Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
J Diabetes Res 2019(9426014)
Oral #Wegovy Approved in Europe The European Medicines Agency (EMA) granted approval for once-daily oral semaglutide (the Wegovy tablet) for the treatment of obesity and overweight, making it the first oral GLP-1 treatment for weight management authorised in the European Union
Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, Vinderola G
To qualify, you need a documented BMI in the obesity range and a related condition such as type 2 diabetes, hypertension, or sleep apnea
Data from an early meta-analysis of 18 trials provided evidence that in people living with T2DM, GLP-1 RAs promote a mean weight loss of 2.8 kg ( 3.4 to 2.3 kg) [116]
A.MunkhaugenJ.MoumT.SverreE.NordhusI
US$ 22.95
US$ 27.60
US$ 28.91
US$ 22.33
